The involvement of oxygenated cholesterol precursors in the regulation of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase activity was studied by examining the effect of ketoconazole on the metabolism of mevalonic acid, lanosterol and the lanosterol metabolites, lanost-8-ene-31,h32-diol, 3,f-hydroxylanost-8-en-32-al and 4,4-dimethylcholesta-8, 14-dien-3,8-ol, in liver subcellular fractions and hepatocyte cultures. Inhibition of cholesterol synthesis from mevalonate by ketoconazole at concentrations up to 30 ,/M was due exclusively to a suppression of cytochrome P-450LDM (LDM = lanosterol demethylase) activity, resulting in a decreased rate of lanosterol 14a-demethylation. No enzyme after the 14a-demethylase step was affected.
INTRODUCTION
One of the means by which cells compensate for changes in cholesterol balance involves modification of the rate of endogenous cholesterol synthesis. This is brought about mainly by changes in the activity of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (EC 1.1.1.34), which regulates carbon flux into the cholesterol pathway [1] . However, the exact sequence of events by which cellular cholesterol status is transmitted to HMG-CoA reductase is poorly understood. Early studies by Kandutsch and his colleagues provided strong evidence that oxygenated cholesterol derivatives may act as second messengers in this process [2] [3] [4] . Sterols of this type occur naturally during cholesterol biosynthesis [1, 5, 6 ], but it is only quite recently that changes in the amounts of these substances have been correlated with changes in the activity of HMG-CoA reductase. These studies involved, mainly, the use of inhibitors of the triterpenoid part of the cholesterol pathway. For instance, inhibition of squalene-2,3-oxide cyclase (EC 5.4.99.7) by the drug U-18666A in intestinal epithelial cells resulted in the formation of squalene-2,3:22,23-dioxide, which was then cyclized by residual enzyme activity to 24, 25 -oxidolanosterol, which accumulated [7, 8] . Similarly, inhibition of lanosterol 14a-demethylation by ketoconazole in liver resulted in increased amounts of the C-32 oxygenated intermediates of the demethylation sequence lanost-8-ene-3,f,32-diol and 3/,-hydroxylanost-8-en-32-al (structures II and III, Scheme 1) [9, 10] . In both cases, there was a decline in the activity of HMG-CoA reductase. The experiments using ketoconazole were of particular interest, since this drug is an inhibitor of cytochrome P-450 [11] , an isoenzyme of which is essential for the oxidative 14a-demethylation of lanosterol during cholesterol biosynthesis [12] [13] [14] [15] . The specificity of enzyme inhibition by ketoconazole, however, has not been clearly defined, and it has been reported that in non-hepatic cells the drug also causes the appearance of other oxygenated sterols, notably the 24,25-oxido derivative of lanosterol [16, 17] . This is convertible into 24,25-oxidocholesterol, a known suppressor of HMG-CoA reductase activity [8] . Similarly, the work of Miettinen has suggested that, with high concentrations in human subjects, the drug interferes with post-lanosterol enzymes of the cholesterol pathway [18] . An objective of the present work was to clarify the effects of ketoconazole on enzymic processes producing oxysterols in the liver and to correlate these effects with HMG-CoA reductase activity. Also, in view of increasing awareness of the possible role of 3fl-hydroxylanost-8-en-32-al as a natural regulator of HMG-CoA reductase activity [10, 17, 19, 20] (10 %, v/v) and other supplements as described previously [22] . At 4 h after the suspension was plated out into dishes, the medium was changed and the cell monolayer was washed three times with the above medium lacking serum. Serum-free medium (3.0 ml) was then added to each dish. [ of the silica-gel obtained in t.l.c. System 1 with diethyl ether. After evaporation of the ether, the sterol fraction was acetylated, followed by t.l.c. on silica-gel G with hexane/diethyl ether (4: 1, v/v) as the solvent (System 2).
The RF values of the 3fl-acetates of cholesterol, the C-32 aldehyde and 24,25-oxidolanosterol were 0.47, 0.33 and 0.28 respectively. To test the efficiency of this system in separating the last two sterols, a mixture of the acetates of the 2-3H-labelled aldehyde and the unlabelled 24,25-oxide were chromatographed. On average, only 11.1 + 2.2 % (S.E.M., n = 6) of the recovered radioactive aldehyde occurred in the fraction containing the 24,25-oxide.
The labelled components of the polar sterol fraction in System 1 (RF 0.09) were also examined after their elution with diethyl ether. In this case, the labelled material was further chromatographed on silica-gel G with ether/ hexane ( [2- '4C]mevalonate as described previously [12] , except that ketoconazole (140 /tM) was used instead of CO to prevent further metabolism into cholesterol. It was extensively purified in several t.l.c. systems before use [12] . Its prepared by chemical synthesis as described previously [19, 21] . They were purified immediately before use by t.l.c. (System 1). Their specific radioactivities were 7600d.p.m./nmol. 4,4-Dimethyl[2-3H]cholesta-8,14-dien-3,l-ol was synthesized from cholesta-5,7-dien-3,8-ol as described previously [14, 26] . It was purified immediately before use by t.l.c. in System 1. Its specific radioactivity was 5799 d.p.m./nmol. 24,25-Oxidolanosterol, a mixture of 24(R)-and 24(S)-epimers, with the former predominating, was given by Dr. Thomas Spencer, Dartmouth College, Hanover, NH, U.S.A. Ketoconazole was given by Mr. N. Blatchford, Janssen Pharmaceuticals, Wantage, Berks., U.K. All organic solvents were distilled before use and, in addition, diethyl ether was passed through a column of alumina (Grade I; Woelm, Eschwege, Germany) to remove any peroxides. Radiochemicals other than those described above were obtained from Amersham International, Little Chalfont, Bucks., U.K. Tissue-culture media were obtained from Gibco (Paisley, Scotland, U.K.). Enzymes and cofactors were obtained from Sigma (U.K.). Thin-layer plates of silicagel G and Alumina G were obtained from Anachem (Luton, Beds., U.K.).
RESULTS

Effects of ketoconazole on sterol formation from 12-'4Clmevalonate
In S16 fractions derived from liver, increasing concentrations of ketoconazole gave rise to an increase in the accumulation of labelled lanosterol, which was accompanied by the decline in the rate of labelled-cholesterol synthesis (Fig. 1) . However, the drug had opposite effects on the accumulation of labelled polar sterols (i.e. total sterols of polarity greater than cholesterol), depending on its concentration. At low concentrations (0.1-1.0,UM) the amounts of these labelled substances increased, whereas at higher drug concentrations (> 1.0 ,m) there was a decline. Subsequent experiments showed that these sterols could be sub-divided by t.l.c. into two classes, the most abundant of which had the greater polarity (RF 0.00-0.07). Fig.   3 . In general, higher concentrations of the drug were required to obtain similar effects to those observed in the subcellular fractions. However, ketoconazole again led to an increase in the amounts of label associated with the lanosterol-containing fraction at the expense of labelled cholesterol. Argentation chromatography of the lanosterol-containing fraction [12] showed that 67% of the radioactivity was associated with lanosterol, 28 % with 24,25-dihydrolanosterol and less than 5%0 with their 14a-demethyl derivatives (C29 sterols). This confirms that the major site of blockage was at the 14ac-demethylation step. These effects were not very pronounced at drug concentrations < 2 ,tM, in contrast with the pattern observed with the subcellular fraction (Fig. 1) . Nevertheless, in the cell cultures over this low concentration range there were increases in the accumulation of label in two fractions more polar than cholesterol (P < 0.01 for the least pollar of these fractions).
Because of the decreased effectiveness of ketoconazole in the hepatocyte culture system, other experiments were carried out at higher concentrations of the drug (Fig. 4) . In this case the labelled contents of the oxysterolcontaining fractions were investigated more thoroughly. First, the labelled C-32 aldehyde was purified from the cholesterol-containing fraction by acetylation, followed by t.l.c. in System 2. Second, the labelled fraction of RF 0.07-0.20 was further resolved (t.l.c. System 3) into two separate fractions, with the mobilities of 25-hydroxycholesterol (RF 0.20) and lanost-8-ene-3/3,32-diol (RF 0.26). Of the oxygenated lanosterol metabolites, only the C-32 aldehyde contained appreciable amounts of label, the quantities of which increased in an almost linear fashion up to a drug concentration of 30 /LM (Fig. 4b) . At this concentration, the label in the C-32 aldehyde amounted to 560 of that in cholesterol and 40 of that in the lanosterol-containing fraction. In contrast with the cell-free system, no biphasic effect of ketoconazole on the labelling of the C-32 aldehyde was observed in the hepatocyte cultures. This may reflect the decreased effectiveness of the drug in whole cells compared with the cell-free model. Concentrations of ketoconazole greater than 30 /tM were visibly toxic to the cells, so no attempts were made to study sterol accumulation in a higher concentration range. Very little label was associated with the C-32 alcohol, the immediate precursor of the C-32 aldehyde, at any concentration of ketoconazole. Most of the radioactivity of the original fraction from which it was derived (RF 0.07-0.20, System 1), corresponded, on subsequent t.l.c., to a fraction with the chromatographic mobility of 25-hydroxycholesterol. The amount of this labelled material reached a maximum at a drug concentration of 5 ,uM (Fig. 4b) . The small amounts of radioactivity precluded any further investigation into the nature of this substance. Ketoconazole again resulted in an increase in the incorporation of label into a very polar sterol fraction (RE 0.00-0.07, System 1). This amount reached a peak at 5 jtM-ketoconazole. Although relatively low concentrations of the drug always gave rise to an increase in the accumulation of label in this fraction, the exact concentration required for maximum labelling varied. In four independent experiments, two reached a maximum at 5 /LM-ketoconazole and two at 10 ,UM.
Response of HMG-CoA reductase to ketoconazole
Treatment of cells with an increasing concentration of ketoconazole gave rise to a decrease in the activity of HMG-CoA reductase measured 6 h later (Fig. 5) . Keto [14, 15, 27] . To obtain more information about the exact sites inhibited by ketoconazole, we studied the effects of the drug on the metabolism of the substrate (lanosterol), an intermediate (lanost-8-ene-3,8,32-diol) and on the product (4,4-dimethylcholesta-8,14-dien-3,I-ol) of the 14a-demethylase enzyme in liver subcellular fractions. These were compared with the effects on the metabolism of mevalonate. Fig. 6(b) shows that the pattern of inhibition of cholesterol formation from lanosterol was almost identical with that from mevalonate, as was the extent of accumulation of label in the C-32 aldehyde (Fig. 6a) and in the amounts of lanosterol remaining at the end of the incubation (Fig. 6c) . However, the conversion of lanost-8-ene-3,8,32-diol into cholesterol was less sensitive to inhibition by ketoconazole, and this was reflected by the smaller quantities of labelled substrate remaining at the end of the incubation (Fig. 6c) . Nevertheless, the relative accumulation of label in the C-32 aldehyde from this substance was much enhanced by ketoconazole, and at the highest concentration of the drug this amounted to almost 10% of the total radioactivity recovered. Keto- conazole had no effect on the metabolism of the product of lanosterol 14a-demethylase, 4,4-dimethylcholesta-8,14-dien-3,f-ol (structure IV, Scheme 1), thereby confirming that, in liver, of all the steroidal steps of cholesterol biosynthesis, ketoconazole at concentrations up to 10 UM interferes exclusively with that requiring cytochrome P-450, i.e. lanosterol 14a-demethylation.
In view of the relative decline in the accumulation of the labelled C-32 aldehyde at high concentrations of ketoconazole in a liver S16 fraction (Fig. 2) when mevalonate was the cholesterol precursor, it was of interest to determine whether the oxygenated cholesterol precursor, lanost-8-ene-3f3,32-diol, behaved in a similar way. This was tested by incubating the diol at drug concentrations up to 30 IM (Fig. 7) . Again, concentrations greater than 10 JiM reversed the accumulation of label in the C-32 aldehyde. Post-mitochondrial (16000 g) supernatants were prepared from rat liver (see Fig. 1 
DISCUSSION
Of all the known enzymes of the triterpenoid part of the cholesterol pathway in liver, ketoconazole inhibited only lanosterol 14a-demethylase. Previous work using non-hepatic cells [16, 17] showed that the drug also inhibited squalene-2,3-oxide cyclase (lanosterol synthase; EC 5.4.99.7). This gave rise, at low concentrations of the drug, to an increase in the accumulation of 24,25-oxidolanosterol. Ketoconazole, at least up to a concentration of 30 4uM, had no such effects on the liver, as shown by the constant levels of label associated with this substance when [2-"C]mevalonate was the cholesterol precursor ( Fig. 2) . It is possible that hepatic and nonhepatic cells respond differently in this respect to ketoconazole. The constancy of 24,25-oxidolanosterol under conditions in which HMG-CoA reductase activity declined (Fig. 5) lends support to the idea that the formation of this compound is not required for a suppression of reductase activity [17] . On the basis of serum sterol profiles in human subjects, it has also been suggested that high concentrations of the drug interfere with other postlanosterol enzymes of cholesterol biosynthesis [18] . In the present work, the lack of any effect of ketoconazole on the formation of cholesterol from 4,4-dimethylcholesta-8,14-dienol, the immediate product of the demethylase reaction [26, 28] , suggested that, in liver subcellular fractions, at drug concentrations up to 10 uM, the post-14a-demethylase part of the pathway remained unperturbed. This also provided evidence that changes in reductase activity (Fig. 5) ----n these was identified as the C-32 aldehyde derivative of lanosterol or 24,25-dihydrolanosterol. This supports the work of Trzaskos and his colleagues [9, 10, 17] and, together with a recent report from Kandutsch's laboratory [20] , provides strong circumstantial evidence for a natural role for this cholesterol precursor in the regulation of HMG-CoA reductase activity. One of the other, less highly labelled, polar sterols which accumulated in hepatocytes cultured with ketoconazole, had the chromatographic properties of 25-hydroxycholesterol, but its precise identity remains unknown. It did not correspond to lanost-8-ene-3fi,32-diol. The remaining oxysterol fraction which accumulated under these conditions was more polar. Again, its identity is not known. How these substances arise, and whether they play a role in the suppression of HMG-CoA reductase activity (Fig. 5) , are questions which remain to be resolved.
The other oxygenated intermediate of lanosterol
demethylation, lanost-8-ene-3fl,32-diol, did not accumulate in the presence of ketoconazole. Nevertheless, its use as a cholesterol precursor led to a ketoconazole-induced accumulation of its immediate product, 3,f-hydroxylanost-8-en-32-al, in greater quantities than those which occurred when mevalonate and lanosterol were the cholesterol precursors. The accumulation of this substance implies that its further metabolism to 4,4-dimethylcholesta-8,14-dienol (structure IV, Scheme 1) is more sensitive to inhibition by ketoconazole than are the oxidative steps required for its formation. However, we have shown previously that when the 3H-labelled C-32 aldehyde was the cholesterol precursor, although its metabolism was inhibited by ketoconazole, the extent of inhibition was less than that of the oxidative metabolism of lanosterol itself [28a] . The metabolism of the C-32 aldehyde was also insensitive to inhibition by CO, another inhibitor of cytochrome P-450 [14] . The kinetics of lanosterol demethylation are exceptionally complex, and this apparent paradox may be related to the increased interaction of the functionalized methyl group with the haem iron of oxidized cytochrome P-450 [29] and to the differential metabolism of enzyme-bound and nonenzyme-bound intermediates during cytochrome P-450-catalysed steroid demethylation [30] . These factors may help to explain the differential accumulation of the C-32 aldehyde when the C-32 alcohol, rather than lanosterol, was used as the cholesterol precursor (Fig. 6) . Apart from its effects on HMG-CoA reductase, ketoconazole induces changes in the expression ofhepatic low-density lipoprotein receptors [18, 31] . The molecular mechanism underlying this effect is unknown, but it seems reasonable to assume that steroidal oxidation(s) requiring cytochrome P-450 are involved. Thus oxysterols generated by this isoenzyme of cytochrome P-450 may be the signal by which information relating to cholesterol balance is transmitted through the cell via a specific oxysterol-binding protein [32] [33] [34] [35] . If this is the case, then factors which regulate cytochrome P-450 activity may play an important role in determining the response of the cell to a shortage or excess of cholesterol.
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